3 ASX healthcare shares up 10% to 22% on news

These healthcare shares are catching the eye on Wednesday. But why?

| More on:
A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There have been some big movers in the healthcare sector on Wednesday.

Here's why these ASX healthcare shares are up over 10% today:

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price is up over 13% to $3.12. Investors have been buying this ASX healthcare share today after it released a quarterly update. Mayne Pharma reported an improved performance during the quarter, with all segments delivering a positive contribution margin. This led to quarterly sales of $92.3 million, a gross margin of 58%, and a cash EBITDA loss of $1.7 million. As a comparison, in the fourth quarter, Mayne Pharma reported sales of $68.2 million, a gross margin of 43%, and a cash EBITDA loss of $19.5 million.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm share price is up 22% to 77 cents. This follows the release of an update on the biopharmaceutical company's injectable pentosan polysulfate sodium (iPPS) treatment. The release notes that iPPS increases cartilage thickness at six months in participants with knee osteoarthritis compared to cartilage loss in placebo group. Management believes the results indicate a treatment effect on osteoarthritis beyond the relief of symptoms and "supports iPPS as a blockbuster opportunity."

Starpharma Holdings Ltd (ASX: SPL)

The Starpharma share price is up 11% to 5 cents. This morning, this ASX healthcare share reported that its DEP cabazitaxel phase two clinical trial met its objectives. Endpoints demonstrated positive antitumour efficacy in multiple cancers and confirmed the product's favourable safety and tolerability profile. Management believes the promising efficacy results in advanced prostate, ovarian, and gastro-oesophageal cancers create a significant market opportunity for DEP cabazitaxel.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Starpharma. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »